Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $SPRB–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. “Our goal with the…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks